Al-Shahi Salman R, Dennis MS, Sandercock PAG, et al. - This study found no statistically significant effect of antiplatelet therapy on recurrent intracerebral hemorrhage (ICH) or all major vascular events in patients with ICH who had previously received antithrombotic therapy. Such findings provide some reassurance to physicians regarding the use of antiplatelet therapy following ICH if indicated for secondary prevention of major vascular events.

• In total, 537 patients (median age, 76.0 years; IQR, 69.0-82.0 years; 360 [67.0%] male; median time after ICH onset, 76.0 days; IQR, 29.0-146.0 days) were randomly assigned to begin (n = 268) or discontinue (n = 269 [1 withdrew]) antiplatelet therapy.

• The primary outcome of recurrent ICH affected 22 of 268 participants (8.2%) assigned to antiplatelet therapy vs 25 of 268 participants (9.3%) assigned to avoid antiplatelet therapy.

• A major vascular event occurred in 72 candidates (26.8%) who were assigned to antiplatelet therapy vs 87 candidates (32.5%) who were assigned to avoid antiplatelet therapy.